indications for glp-1 agonists The science on receptor has outpaced the public narrative. While headlines chase the latest prescription numbers, evidence-based practice demands we hold the line: obesity is a chronic, relapsing condition; not GLP-1 agonists for weight loss:

Most symptoms are most pronounced during dose escalation phases and tend to diminish within 4-8 weeks of maintaining a stable dose

For a long time, the manifestation of depressive symptoms has been also associated with the deficits in neurotrophic factor action in the brain [51], especially highlighting the role of diminished brain-derived neurotrophic factor (BDNF) signaling as important for the pathogenesis of this mental disorder [52]

Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression

Conversion charts exist to help guide dosing during these within-class switches

doi: 10.1089/thy.2014.0028 [DOI] [PMC free article] [PubMed] [Google Scholar] 174.De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J